Substance Use Disorders Clinical Trial
Official title:
From Addiction to Employment. Effectiveness of Employment Support During Treatment for Substance Use Disorders. The Individual Placement and Support (IPS-SUD) Trial.
Patients with substance use disorders have low employment rates and are to a large extent on the outside of the ordinary labor market. Individual Placement and Support (IPS) is an evidence based method developed to aid persons with severe mental disorders in obtaining ordinary work. IPS has been used clinically in the addiction field, but has been subject to little research. The trial "From addiction to employment" is a randomized controlled trial to investigate the effect of an IPS intervention on employment outcome among substance use disorder patients in specialized health care treatment in Oslo, Norway. The study is conducted at the Department for Substance Use Disorder Treatment at Oslo University Hospital. The trial begins to include patients March 1st 2020 and will include for two years, until February 28th 2022.
The target population in this project is patients in SUD treatment who wish to gain employment. The goal of the study is to determine the effectiveness of IPS in helping persons with SUD obtain ordinary employment. A pragmatic, two-arm, parallel, superiority, randomized controlled trial will be conducted. The project is financed through innovation funding from the South Eastern Norway Regional Health Authority, the Norwegian Directorate of Health and internal resources from OUS. Participants will be allocated randomly to either an employment specialist whom they will have individual contact with for the coming 13 months or shorter (intervention), or to a self-help and four-sessions work shop intervention (control comparison). The intervention fidelity will be assessed by external evaluators according to the Norwegian translation of the IPS Fidelity Scale. Patients will be recruited to the study over a period of two years, and followed for 18 months my data collection and up until 10 years in national registries. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05660434 -
Using Aromatherapy in Substance Use Disorder
|
N/A | |
Active, not recruiting |
NCT05338268 -
Substance Use and Loneliness
|
N/A | |
Completed |
NCT04098614 -
Barriers to Substance Use Disorder Recovery
|
N/A | |
Completed |
NCT03954184 -
E-health Implementation (Iowa)
|
N/A | |
Completed |
NCT03590106 -
Cardiac Surgery Peer Recovery Support Program
|
N/A | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Recruiting |
NCT06273228 -
Parenting Young Children in Pediatrics
|
N/A | |
Recruiting |
NCT05327504 -
Written Exposure Therapy for Veterans With SUD and PTSD
|
N/A | |
Terminated |
NCT03517111 -
The Impact of a Parenting Intervention on Latino Youth Health Behaviors
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT04401215 -
Technologically-Augmented Referrals to Mitigate Addiction Consequences
|
N/A | |
Not yet recruiting |
NCT06163651 -
Evaluating a One-Year Version of the Parent-Child Assistance Program
|
N/A | |
Not yet recruiting |
NCT06187701 -
Co-Active Therapeutic Theatre (Co-ATT) for Dual-Diagnosis Patients
|
N/A | |
Recruiting |
NCT04296604 -
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
|
N/A | |
Active, not recruiting |
NCT02382042 -
Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans
|
N/A | |
Completed |
NCT01237366 -
Study Targeting Affect Regulation
|
Phase 1/Phase 2 | |
Terminated |
NCT01356667 -
Drum-Assisted Therapy for Native Americans
|
N/A | |
Completed |
NCT00708890 -
Twelve Step Based Self-help Groups for Substance Related Disorders
|
N/A | |
Active, not recruiting |
NCT04048850 -
Zepatier in Patients With Substance Use
|
||
Recruiting |
NCT05976646 -
Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion
|
Phase 1/Phase 2 |